In a 28-year-old female patient with extensive cutaneous LP, we took advantage of the availability of Secukinumab, an anti-IL-17A monoclonal antibody which is approved for the treatment of psoriasis vulgaris. This evidence concerns the gene IL17A and psoriasis vulgaris.